celgene stock price forecast

Still, the average price target on the stock is about $118.60, and that represents a 28 percent upside from the stock's current price of $92.60. But some expect the stock to go even higher; RBC has Celgene rated as a top pick and set a $131 price target. (See also: Target Prices: The Key to Sound Investing.)

Full Answer

Is BeiGene efficiently growing its dividend?

BeiGene does not have a long track record of dividend growth. In the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,366,713.00 in company stock. Only 8.90% of the stock of BeiGene is held by insiders.

Is BeiGene a buy or sell on Wall Street?

BeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $390.00, BeiGene has a forecasted upside of 55.1% from its current price of $251.45.

When is BeiGene's next quarterly earnings announcement?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for BeiGene. How were BeiGene's earnings last quarter? BeiGene, Ltd. (NASDAQ:BGNE) announced its earnings results on Thursday, November, 4th.

Who holds BeiGene's stock?

Only 8.90% of the stock of BeiGene is held by insiders. 54.78% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for BeiGene are expected to decrease in the coming year, from ($12.64) to ($14.23) per share.

See more

What is the price of Celgene?

108.24Key Turning Points52-Week High110.70Last Price108.24Fibonacci 61.8%90.79Fibonacci 50%84.64Fibonacci 38.2%78.501 more row•Nov 20, 2019

Can I still buy Celgene stock?

It's not too late to buy Celgene stock at all -- as long as you hold on to the Bristol-Myers Squibb stock you get when the acquisition closes.

Why did Celgene stock drop?

The stock has been hit by multiple rounds of bad news regarding its drug pipeline amid concerns about its growth outlook. But the market may have turned too negative on Celgene, with analysts looking for the stock to rise by roughly 28 percent, and currently trading with a 2019 P/E ratio below 10.

What happened Celgene stock?

The Celgene shares were delisted from the NASDAQ stock exchange and are no longer trading.

Why did BMS buy Celgene?

The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities.

What do Celgene shareholders get?

Under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are ...

Is Celgene now BMS?

Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company.

Who bought Celgene?

Bristol-Myers SquibbBy erasing one of the industry's most active partners, the $74 billion deal promises to shake up biotech for years to come.

Can CVRs be traded?

CVRs can be transferable, which are listed on an exchange, and non-transferable.

What happened to Bristol Myers?

Merger. In 1989, Bristol-Myers and Squibb merged and became Bristol-Myers Squibb.

What products does Celgene have?

Products. As of 2019, Celgene focused on oncology and immunology. Cancer drugs include Revlimid (lenalidomide) and Pomalyst (pomalidomide) and the immunology drug Otezla (apremilast) accounted for around 90% of the company's total revenue as of 2019.

Is Celgene a publicly traded company?

Celgene became a subsidiary of BMS and is no longer a publicly traded company on its own.

Is Bristol-Myers Squibb a good stock to buy?

Bristol-Myers has multiple top-selling drugs in its portfolio that generate billions in revenue. The company is a money-making machine that could bring in $50 billion in free cash over the next few years. Its low valuation and high dividend yield make it an all-around safe stock to just buy and hold.

Who bought out Celgene?

Bristol-Myers SquibbBy erasing one of the industry's most active partners, the $74 billion deal promises to shake up biotech for years to come.

Is AbbVie a good stock?

Third, AbbVie is an excellent stock for dividend-seeking investors. The company offers a juicy yield of 3.67%-- which is much higher than the S&P 500's yield of 1.37%.

When did Bristol-Myers buy Celgene?

November 21, 2019Celgene common stock ceased trading as of the close of trading today. On November 21, 2019, newly issued Bristol-Myers Squibb shares and CVRs will commence trading on the New York Stock Exchange, with the CVRs trading under the symbol “BMYRT.”

"Should I invest in Celgene stock?" "Should I trade "CELGZ" stock today?"

According to our live Forecast System, Celgene Corp. stock is a good long-term (1-year) investment *.

What is the Celgene stock price / share price today?

The Celgene stock price is 0.440 USD today.

Will Celgene stock price grow / rise / go up?

Yes. The CELGZ stock price can go up from 0.440 USD to 0.489 USD in...

Is it profitable to invest in Celgene stock?

Yes. The long-term earning potential is + 11.23 % in one year.

Will CELGZ stock price fall / drop?

No. See above .

What will Celgene stock price be worth in five years (2027)?

The CELGZ ("CELGZ" ) future stock price will be 0.000001 USD .

Will CELGZ stock price crash?

According to our analysis, this will not happen.

Will Celgene stock price hit 1 USD price in a year?

Not within a year. See above .

Will Celgene stock price hit 5 USD price in a year?

Not within a year. See above .